Huadong Medicine’s HDM1010 Gets FDA Nod for Phase I Trial in T2D
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the...
Drug
AstraZeneca’s Calquence Combo Approved by EU for CLL Treatment
UK-based pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) announced that the European Commission (EC) has approved its...
Bayer’s CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD
German pharmaceutical giant Bayer AG (ETR: BAYN) announced results from the Phase II CONFIDENCE study,...
NeoCura Bio-Medical Gains NMPA Approval for mRNA Cancer Vaccine Trial
China-based NeoCura Bio-Medical Technology Co., Ltd. announced that it has received approval from the National...
YolTech Receives FDA Clearance for PCSK9-Targeted Base Editing Drug YOLT-101
Shanghai-based YolTech Therapeutics announced that it has received clearance from the US Food and Drug...
HELP Therapeutics’ iPSC-Derived Cardiomyocyte Therapy Enters US Clinical Trials
Nanjing-based HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company, announced that its innovative induced...
Bayer’s Vividion Gains Global Rights to WRN Inhibitor VVD-214
German pharmaceutical giant Bayer AG (ETR: BAYN) announced that its wholly owned subsidiary Vividion Therapeutics,...
Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Study of SHR-A1811, Adebrelimab and Famitinib in Solid Tumors
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...
Lianhuan Pharma Gains NMPA Approval for No-Spa Generic
China-based Jiangsu Lianhuan Pharmaceutical Co., Ltd (SHA: 600513) announced that it has received market clearance...
Roche’s Evrysdi 5mg Tablet Gains EU Commission Approval for Spinal Muscular Atrophy
Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced that the European Commission (EC) has...
Sunshine Guojian’s SSGJ-613 Meets Phase III Endpoints in Acute Gouty Arthritis
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...
Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from CDE
China-based Innovent Biologics, Inc. (HKG: 1801) announced that its first-in-class PD-1/IL-2α-bias bispecific antibody (BsAb) fusion...
BMS Secures NMPA Approval for Reblozyl in Myelodysplastic Syndromes
US-based multinational Bristol-Myers Squibb (BMS, NYSE: BMY) announced that it has received an indication extension...
AstraZeneca’s Imfinzi Approved for Limited Stage Small Cell Lung Cancer in China
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) received approval from China’s National Medical Products Administration...
Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication
China-based Akeso Biopharma (HKG: 9926) announced that it has received another indication approval from the...
Salubris Pharmaceuticals’ Allisartan-Indapamide Hybrid Wins NMPA Approval
Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a Chinese pharmaceutical company, announced that it has...
Wantai Biopharm’s Cecolin 9 HPV Vaccine Approved by China’s NMPA
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its 9-valent human...
Biocytogen and Chia Tai Tianqing Win NMPA Approval for NTB003 Clinical Trials
Chinese partners Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) and Chia Tai Tianqing announced that...
NMPA Accepts NDA for Innovent and HutchMed’s Tyvyt and Elunate Combination
Chinese companies Innovent Biologics, Inc. (HKG: 1801) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013)...
JW Therapeutics’ Carteyva Approved by Macau Health Bureau
JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics...